(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual revenue growth rate of -24.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Orchestra Biomed Holdings's revenue in 2026 is $33,482,000.On average, 10 Wall Street analysts forecast OBIO's revenue for 2026 to be $46,213,019, with the lowest OBIO revenue forecast at $32,747,126, and the highest OBIO revenue forecast at $61,446,946. On average, 7 Wall Street analysts forecast OBIO's revenue for 2027 to be $46,111,544, with the lowest OBIO revenue forecast at $0, and the highest OBIO revenue forecast at $85,440,515.
In 2028, OBIO is forecast to generate $1,009,368,500 in revenue, with the lowest revenue forecast at $315,427,656 and the highest revenue forecast at $2,270,493,917.